10-Q: Nuo Therapeutics Reports Q3 2026 Results, Faces Going Concern Doubt

Nuo Therapeutics, Inc. reported increased revenues for Q3 2026, but continues to face substantial doubt regarding its ability to continue as a going concern.

Summary

• Nuo Therapeutics, Inc. reported total revenues of $1.87 million for the third quarter of 2026, an increase of 81% compared to $1.03 million in the same period of 2025.
• For the nine months ended September 30, 2026, total revenues were $4.94 million, a 122% increase from $2.22 million in the prior year period.
• The company reported a net loss of $0.42 million for Q3 2026, compared to a net loss of $0.54 million in Q3 2025.
• For the nine months ended September 30, 2026, the net loss was $1.32 million, an improvement from $1.93 million in the same period of 2025.
• Despite revenue growth, the company continues to have substantial doubt about its ability to continue as a going concern due to recurring losses and limited cash resources.
• The company received $1.175 million in net proceeds from the issuance of secured notes payable during the nine months ended September 30, 2026.
• A significant risk factor is the interruption in the supply of bovine thrombin (TJMI), a key reagent for the Aurix System, with resupply estimated for Q2 2027.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued substantial doubt about its ability to continue as a going concern, despite revenue growth.

Positives

• Total revenues increased by 81% to $1.87 million for the three months ended September 30, 2026, compared to $1.03 million in the prior year period.
• Product revenues increased by approximately 86% to $1.78 million for the three months ended September 30, 2026, compared to $957,000 in the prior year period.
• Gross profit increased by approximately 91% to $1.19 million for the three months ended September 30, 2026, compared to $625,000 in the prior year period.
• Gross margin improved to approximately 64% for the three months ended September 30, 2026, from approximately 61% in the prior year period.
• For the nine months ended September 30, 2026, total revenues increased by 122% to $4.94 million, and gross profit increased by 110% to $3.21 million.
• The company received $1.175 million in net proceeds from the issuance of secured notes payable during the nine months ended September 30, 2026.
• The company received a $250,000 milestone payment in August 2026 related to the distribution agreement with Smith+Nephew.

Negatives

• The company has an accumulated deficit of approximately $36.1 million as of September 30, 2026.
• Stockholders' deficit was approximately $1.8 million as of September 30, 2026.
• Cash balance was approximately $0.1 million as of September 30, 2026.
• Total current liabilities of approximately $2.5 million exceeded total current assets of approximately $2.0 million as of September 30, 2026.
• The company incurred a net loss of $0.42 million for Q3 2026 and $1.32 million for the nine months ended September 30, 2026.
• Operating expenses increased by approximately $402,000 to $1.57 million for Q3 2026 compared to Q3 2025.
• Operating expenses increased by approximately $733,000 to $4.20 million for the nine months ended September 30, 2026, compared to the prior year period.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and limited cash resources.
• The company experienced an interruption in the supply of bovine thrombin (TJMI), a key reagent for the Aurix System, with resupply estimated for the second quarter of 2027.
• The TJMI supply interruption caused the Aurix product to enter a temporary out-of-stock situation for approximately two weeks in early August 2026.
• The company may be unable to obtain, utilize, or establish long-term alternative supplies or suppliers of thrombin at acceptable prices or quality levels.
• Pfizer may unilaterally raise the price or alter its allocation of TJMI, or decline to renew or terminate the supply agreement.
• Reliance on single suppliers for certain components poses a risk of interruption or inability to meet customer demand.
• The company's ability to secure sufficient capital to fund operating activities is uncertain, and failure to do so may force delays or reductions in its business plan.
• Any future equity financing may cause substantial dilution to stockholders, and debt financing may impose onerous covenants.

Future Outlook

The company's future outlook is uncertain due to its ongoing need for substantial capital and the existence of substantial doubt about its ability to continue as a going concern. Management is actively pursuing plans to mitigate liquidity constraints, including securing additional equity financing and the October 2026 Second Funding, but success is not assured. The company anticipates continued revenue growth but requires additional capital for foreseeable future operations.

Management Comments

• "We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products and the Private Label product to Smith+Nephew are insufficient to support our operations for the next 12 months from the date these financial statements are issued. As such, we believe that substantial doubt about our ability to continue as a going concern exists."
• "In response to these conditions, management is actively pursuing plans to mitigate these liquidity constraints, which include the October 2026 Second Funding... and securing additional equity financing; however, there can be no assurance that management's plans will be successful."
• "We may not be able to obtain additional capital as required to finance our efforts, through equity or debt financing, other transactions, or any combination thereof, on satisfactory terms or at all."

Industry Context

StockSavvy.ai notes that Nuo Therapeutics operates in the advanced wound care market, which is substantial but competitive. The company's reliance on the Aurix System and its recent supply chain issues for a key reagent highlight the inherent risks in the medical device sector, particularly concerning manufacturing and regulatory compliance. The favorable CMS National Coverage Determination for autologous PRP in 2021 was a significant positive development, but ongoing reimbursement dynamics and supply chain stability remain critical factors.

Comparison to Industry Standards

• The advanced wound care market was estimated at $10.8 billion globally in 2021, with North America accounting for $4.15 billion in 2020. Nuo Therapeutics' revenue of approximately $4.94 million for the first nine months of 2026 indicates a small market share, typical for a niche player.
• The company's gross margin of approximately 65% for the nine months ended September 30, 2026, is within a reasonable range for medical device companies, though it experienced a slight decline due to pricing on private label sales.
• The company's net loss of $1.32 million for the nine months ended September 30, 2026, reflects the typical investment phase for many medical device companies focused on commercialization and market penetration, rather than immediate profitability.
• The company's cash position of $0.1 million and accumulated deficit of $36.1 million highlight a common challenge for early-stage or commercializing medical device companies that require significant capital investment before achieving sustainable profitability.

Corporate Governance

Legal Proceedings

• There are currently no claims or actions pending against the company, the ultimate disposition of which could have a material adverse effect on its results of operations, financial condition, or cash flows.

Related Party Transactions

• The loan amount from a related party and director of Nuo increased to $300,000 and had a fair value of $323,000 at September 30, 2026.
• The related party loaned $125,000 in the Second Funding, representing an aggregate funding of $425,000 by the related party.

Stakeholder Impact

• Shareholders may experience further dilution if the company secures additional equity financing.
• Creditors and lenders face increased risk due to the company's going concern issues and the secured nature of the debt.
• Employees may face uncertainty regarding job security given the company's financial condition and ongoing operational challenges.
• Suppliers may face payment delays or risks if the company's liquidity issues persist.

Next Steps

• Management is actively pursuing plans to mitigate liquidity constraints, including securing additional equity financing and the October 2026 Second Funding.
• The company will continue to engage and establish relationships with providers treating chronic non-healing wounds to demonstrate the clinical benefits of Aurix.
• The company will continue to develop relationships with clinical providers and treatment facilities by establishing distributor and sales agent arrangements.
• The company is continuing to pursue longer-term alternative approaches, supplies, and suppliers of thrombin to use in the Aurix product line.
• The company intends to implement further measures to improve internal control over financial reporting to remediate identified material weaknesses.

Key Dates

Recommendation

The company's persistent going concern issues, significant accumulated deficit, and critical reagent supply chain disruption, despite revenue growth, present substantial risks. The need for continuous external financing and potential dilution further weigh against a positive outlook, making it a speculative investment.

Keywords

Nuo Therapeutics, Aurix System, wound care, platelet rich plasma, medical device, Smith+Nephew, reagent supply, going concern